Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 16.4.2018 | EN | Official Journal of the European Union | C 134/19 |

---

Judgment of the General Court of 27 February 2018 — Hansen Medical v EUIPO — Covidien (MAGELLAN)

(Case T-222/16)[(1)](#ntr1-C_2018134EN.01001901-E0001)

((EU trade mark - Revocation proceedings - EU word mark MAGELLAN - Genuine use - Burden of proof - Article 15 and Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 18 and Article 58(1)(a) of Regulation (EU) 2017/1001) - Procedural irregularity committed by the Cancellation Division - Obligation to state reasons - Article 75 of Regulation No 207/2009 (now Article 94 of Regulation 2017/1001) - Oral proceedings - Article 77 of Regulation No 207/2009 (now Article 96 of Regulation 2017/1001)))

(2018/C 134/25)

Language of the case: English

Parties

Applicant: Hansen Medical, Inc. (Mountain View, California, United States) (represented by: R. Kunze, G. Würtenberger and T. Wittmann, lawyers)

Defendant: European Union Intellectual Property Office (represented by: D. Gája and by D. Walicka, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Covidien AG (Neuhausen am Rheinfall, Switzerland) (represented by: R. Ingerl and D. Wiedemann, lawyers)

Re:

Action brought against the decision of the Second Board of Appeal of EUIPO of 3 February 2016 (Cases R 3092/2014-2 and R 3118/2014-2), relating to revocation proceedings between Hansen Medical and Covidien.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Hansen Medical, Inc. to pay the costs. |

---

[Top](#document1)